Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/25000516http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/25000516http://www.w3.org/2000/01/rdf-schema#comment"

Aims

The cytosolic 5'-nucleotidase-III (NT5C3) is involved in the metabolism of the nucleoside analog, cytosine arabinose (AraC), and the expression level of NT5C3 is correlated with sensitivity to AraC in acute myeloid leukemia (AML) patients. The current study examined whether the NT5C3 polymorphisms could affect chemotherapy outcomes in 103 Korean AML patients.

Methods

Forty-seven single nucleotide polymorphisms in NT5C3 were genotyped using the Illumina GoldenGate genotyping assay. The genetic effects of the polymorphisms on the outcome of chemotherapy were analyzed using χ and logistic regression models.

Results

Although none of the NT5C3 polymorphisms was associated with a complete remission rate, a common single nucleotide polymorphism, rs3750117, showed a significant association with induction rate after the first course of chemotherapy (Pcorr=0.004 and odds ratio=11.28) in AML patients. In addition, NT5C3 expression levels were significantly increased in patients with risk allele homozygote.

Conclusions

The data suggest that genotyping the NT5C3 polymorphism may have the potential to identify patients more likely to respond to AraC-based chemotherapy."xsd:string
http://purl.uniprot.org/citations/25000516http://purl.org/dc/terms/identifier"doi:10.1097/fpc.0000000000000072"xsd:string
http://purl.uniprot.org/citations/25000516http://purl.uniprot.org/core/author"Lee C."xsd:string
http://purl.uniprot.org/citations/25000516http://purl.uniprot.org/core/author"Ahn K.S."xsd:string
http://purl.uniprot.org/citations/25000516http://purl.uniprot.org/core/author"Yoon S.S."xsd:string
http://purl.uniprot.org/citations/25000516http://purl.uniprot.org/core/author"Shin H.D."xsd:string
http://purl.uniprot.org/citations/25000516http://purl.uniprot.org/core/author"Cheong H.S."xsd:string
http://purl.uniprot.org/citations/25000516http://purl.uniprot.org/core/author"Koh Y."xsd:string
http://purl.uniprot.org/citations/25000516http://purl.uniprot.org/core/date"2014"xsd:gYear
http://purl.uniprot.org/citations/25000516http://purl.uniprot.org/core/name"Pharmacogenet Genomics"xsd:string
http://purl.uniprot.org/citations/25000516http://purl.uniprot.org/core/pages"436-441"xsd:string
http://purl.uniprot.org/citations/25000516http://purl.uniprot.org/core/title"NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia."xsd:string
http://purl.uniprot.org/citations/25000516http://purl.uniprot.org/core/volume"24"xsd:string
http://purl.uniprot.org/citations/25000516http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/25000516
http://purl.uniprot.org/citations/25000516http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/25000516
http://purl.uniprot.org/uniprot/#_A0A090N7U2-mappedCitation-25000516http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/25000516
http://purl.uniprot.org/uniprot/#_Q9H0P0-mappedCitation-25000516http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/25000516
http://purl.uniprot.org/uniprot/Q9H0P0http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/25000516
http://purl.uniprot.org/uniprot/A0A090N7U2http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/25000516